Last reviewed · How we verify

Vesomni® — Competitive Intelligence Brief

Vesomni® (Vesomni®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1A antagonist / Beta-3 agonist combination. Area: Urology.

phase 3 Alpha-1A antagonist / Beta-3 agonist combination Alpha-1A adrenergic receptor; Beta-3 adrenergic receptor Urology Small molecule Live · refreshed every 30 min

Target snapshot

Vesomni® (Vesomni®) — Eurofarma Laboratorios S.A.. Vesomni is a combination of silodosin (alpha-1A adrenergic antagonist) and mirabegron (beta-3 adrenergic agonist) that addresses both obstructive and storage symptoms of benign prostatic hyperplasia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Vesomni® TARGET Vesomni® Eurofarma Laboratorios S.A. phase 3 Alpha-1A antagonist / Beta-3 agonist combination Alpha-1A adrenergic receptor; Beta-3 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1A antagonist / Beta-3 agonist combination class)

  1. Eurofarma Laboratorios S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vesomni® — Competitive Intelligence Brief. https://druglandscape.com/ci/vesomni. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: